Results 201 to 210 of about 137,002 (346)

History of glucagon-like peptide-1 receptor agonists

Pharmacological Research
Radwan Darwish, Ghena Abu-Sharia, Alexandra E. Butler   +2 more
doaj   +1 more source

Should glucagon‐like peptide‐1 receptor agonist treatment be withheld in preoperative management?

Journal of Diabetes, 2023
Zachary Bloomgarden
doaj   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists for Arthritis and Osteoarthritis. [PDF]

Cureus
Nashwan AJ.
europepmc   +1 more source

Slow Transit Constipation: Pathophysiological Perspectives and Management Updates

Journal of Digestive Diseases, EarlyView.
Slow transit constipation (STC) is a complex neuromuscular disorder driven by interstitial cells of Cajal (ICCs) loss and enteric neuropathy. Diagnosis relies on objective transit testing while excluding pelvic floor dysfunction. Management follows a stepwise, phenotype‐driven approach, progressing from conventional laxatives to emerging targeted ...
Athanasios Syllaios, Stavros P. Papadakos, Alexandros Ioannou, Maximos Frountzas, Dimosthenis Michelakis, Dimitrios Patsouras, Spyridon Dritsas, Manousos‐Georgios Pramateftakis, Dimitrios Schizas   +8 more
wiley   +1 more source

Effects of glucagon-like peptide-1 receptor agonists on psychiatric disorders: a systematic review. [PDF]

Ther Adv Psychopharmacol
Lee S, Yin L, Teopiz KM, Wong S, Han Le G, Xiao N, Stahl S, Valentino K, Ho R, Zhang MC, Greg Rhee T, McIntyre RS.   +11 more
europepmc   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Peri‐operative fasting in adults: an international, multidisciplinary consensus statement

Anaesthesia, EarlyView.
Summary Introduction Evidence suggests that existing pre‐operative fasting guidelines are associated with prolonged fasting times. Prolonged fasting, particularly from clear liquids, has the potential to harm patients through reduced peri‐operative wellbeing; impaired glucose metabolism and peri‐operative inflammatory response; delayed return of bowel ...
Anne Rüggeberg, Kariem El‐Boghdadly, Federico Bilotta, Marta Dias Vaz, Anne Marie Camilleri Podesta, Ib Jammer, Ehrenfried Schindler, Jamie Elmawieh, Alexander Nagrebetsky   +8 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists in Plastic Surgery: Perioperative Considerations and Safety Protocols. [PDF]

Cureus
Davila Diaz R, Campos Barrera E, Diaz Fosado LA, Reyes Esparza A, Perez Benitez OA.   +4 more
europepmc   +1 more source

Identification of MEF2A, MEF2C, and MEF2D interactomes in basal and Fsk‐stimulated mouse MA‐10 Leydig cells

Andrology, EarlyView.
Abstract Background Myocyte enhancer factor 2 transcription factors regulate essential transcriptional programs in various cell types. The activity of myocyte enhancer factor 2 factors is modulated through interactions with cofactors, chromatin remodelers, and other regulatory proteins, which are dependent on cell context and physiological state.
Karine de Mattos, Marie‐Pier Scott‐Boyer, Arnaud Droit, Robert S. Viger, Jacques J. Tremblay   +4 more
wiley   +1 more source

Mechanisms of Glucagon-Like Peptide 1 Receptor Agonist-Induced Facial Lipodystrophy and a Path Toward Prevention. [PDF]

J Cosmet Dermatol
Kruglikov IL.
europepmc   +1 more source